Innovative therapies for better lives
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. A Phase 1a clinical trial has demonstrated a good safety and tolerability profile and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.